Blab Business
Health Catalyst Names Simeon Kohl CEO Amid AI-Focused Restructuring
Health Catalyst Inc. announced on Tuesday that Simeon Kohl will assume the roles of chief executive officer, president, and a board member effective September 14, 2026. The change follows Ben Albert’s transition to chief business officer and departure from the board on September 13, marking the company’s third CEO swap this year after Dan Burton’s February retirement.
Kohl arrives with more than twenty years of experience in healthcare operations. His LinkedIn profile notes that he led Performant Healthcare as chief executive from 2023 until its sale to Machinify in October 2025 for roughly $670 million. Performant specialized in helping payers ensure accurate claims billing, a skill set that aligns with Health Catalyst’s data‑integration mission.
The leadership shift comes as the Salt Lake City‑based firm accelerates its artificial‑intelligence (AI) agenda and refines its balance sheet. In July, Health Catalyst sold its revenue‑cycle unit, Vitalware, to Med‑Metrix for $147 million. The divestiture was intended to free capital for AI investments in the core platform that consolidates disparate healthcare data.
The Vitalware sale, announced in June and completed on July 31, has already influenced the company’s financials. Health Catalyst reported a 13 percent drop in revenue for the second quarter of 2026 compared with the same period a year earlier. Executives told investors that the decline stemmed from the transaction and from the ongoing migration of customers onto new data systems.
Health Catalyst’s platform aggregates clinical, financial, and operational data from multiple sources, giving providers a unified view. The company serves more than 1,100 healthcare organizations worldwide—including hospitals, health systems, and physician groups—by enabling streamlined data workflows and predictive analytics.
Kohl’s background in large‑scale operations and his experience with a successful acquisition at Performant suggest a focus on scaling the AI‑driven platform while steering the company away from revenue‑cycle services. The board’s decision to bring him on board reflects a desire for continuity in strategic direction.
Albert, who stepped into the CEO role in February, will now oversee commercial and partnership initiatives as chief business officer. His board exit on September 13 precedes Kohl’s arrival, aligning with a broader reshuffling that has seen Health Catalyst appoint a new chief business officer.
According to the company’s public filings, the strategy centers on concentrating resources on AI capabilities that enhance data integration, predictive analytics, and operational efficiency for clients. Leadership has repeatedly emphasized the importance of a strong balance sheet to support these investments.
The recent revenue decline is described by executives as a short‑term effect of the Vitalware sale and customer migration. In its latest earnings call, the firm noted that the revenue‑cycle business had been a significant contributor to top‑line growth, and its divestiture will require the platform to absorb that loss.
Industry observers view the leadership change as a signal that Health Catalyst is positioning itself for a longer‑term AI‑centric model. The platform has already attracted attention from health systems seeking to streamline data workflows and improve clinical decision support.
As Health Catalyst prepares for the next earnings cycle, investors will monitor how the new CEO balances AI development with revenue recovery. The board’s composition, now including Kohl, will also be scrutinized as it evaluates the impact of the transition on strategic priorities.
In summary, Health Catalyst’s appointment of Simeon Kohl as CEO, president, and board member marks a strategic shift toward AI and a tighter focus on its core data platform. The recent divestiture of Vitalware and the resulting revenue decline underscore the transitional nature of its current business model. Upcoming earnings reports and investor meetings will reveal how the new leadership addresses these challenges and positions the company for future growth.
Kohl arrives with more than twenty years of experience in healthcare operations. His LinkedIn profile notes that he led Performant Healthcare as chief executive from 2023 until its sale to Machinify in October 2025 for roughly $670 million. Performant specialized in helping payers ensure accurate claims billing, a skill set that aligns with Health Catalyst’s data‑integration mission.
The leadership shift comes as the Salt Lake City‑based firm accelerates its artificial‑intelligence (AI) agenda and refines its balance sheet. In July, Health Catalyst sold its revenue‑cycle unit, Vitalware, to Med‑Metrix for $147 million. The divestiture was intended to free capital for AI investments in the core platform that consolidates disparate healthcare data.
The Vitalware sale, announced in June and completed on July 31, has already influenced the company’s financials. Health Catalyst reported a 13 percent drop in revenue for the second quarter of 2026 compared with the same period a year earlier. Executives told investors that the decline stemmed from the transaction and from the ongoing migration of customers onto new data systems.
Health Catalyst’s platform aggregates clinical, financial, and operational data from multiple sources, giving providers a unified view. The company serves more than 1,100 healthcare organizations worldwide—including hospitals, health systems, and physician groups—by enabling streamlined data workflows and predictive analytics.
Kohl’s background in large‑scale operations and his experience with a successful acquisition at Performant suggest a focus on scaling the AI‑driven platform while steering the company away from revenue‑cycle services. The board’s decision to bring him on board reflects a desire for continuity in strategic direction.
Albert, who stepped into the CEO role in February, will now oversee commercial and partnership initiatives as chief business officer. His board exit on September 13 precedes Kohl’s arrival, aligning with a broader reshuffling that has seen Health Catalyst appoint a new chief business officer.
According to the company’s public filings, the strategy centers on concentrating resources on AI capabilities that enhance data integration, predictive analytics, and operational efficiency for clients. Leadership has repeatedly emphasized the importance of a strong balance sheet to support these investments.
The recent revenue decline is described by executives as a short‑term effect of the Vitalware sale and customer migration. In its latest earnings call, the firm noted that the revenue‑cycle business had been a significant contributor to top‑line growth, and its divestiture will require the platform to absorb that loss.
Industry observers view the leadership change as a signal that Health Catalyst is positioning itself for a longer‑term AI‑centric model. The platform has already attracted attention from health systems seeking to streamline data workflows and improve clinical decision support.
As Health Catalyst prepares for the next earnings cycle, investors will monitor how the new CEO balances AI development with revenue recovery. The board’s composition, now including Kohl, will also be scrutinized as it evaluates the impact of the transition on strategic priorities.
In summary, Health Catalyst’s appointment of Simeon Kohl as CEO, president, and board member marks a strategic shift toward AI and a tighter focus on its core data platform. The recent divestiture of Vitalware and the resulting revenue decline underscore the transitional nature of its current business model. Upcoming earnings reports and investor meetings will reveal how the new leadership addresses these challenges and positions the company for future growth.
